Foamix

News

Israel's Foamix has said it is planning a US filing of its minocycline-based topical acne treatment after positive late stage trial results.

News

Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.